Mark Albert Marzinke, Ph.D.

Headshot of Mark Albert Marzinke
  • Director, General Chemistry, The Johns Hopkins Hospital
  • Professor of Pathology


Dr. Mark Marzinke is Professor of Pathology and Medicine at the Johns Hopkins University School of Medicine. Dr. Marzinke serves as the Director of General Chemistry in the Johns Hopkins Hospital Core Laboratories, and is the Director of the Clinical Pharmacology Analytical Laboratory within the Division of Clinical Pharmacology. He is also Co-Director of the HIV Prevention Trials Network Laboratory Center.

He received his A.B. from the College of the Holy Cross and earned his Ph.D. at the University of Wisconsin-Madison. He completed a fellowship in clinical chemistry at the Johns Hopkins School of Medicine more


  • Director, General Chemistry, The Johns Hopkins Hospital
  • Director Clinical Pharmacology Analytical Laboratory
  • Professor of Pathology
  • Professor of Medicine

Departments / Divisions



  • B.A.; College of the Holy Cross (Massachusetts) (2004)
  • Ph.D.; University of Wisconsin (Madison) (Wisconsin) (2010)

Research & Publications

Research Summary

Dr. Marzinke's primary research interest is in the development of bioanalytical tools to better characterize pharmacokinetic-pharmacodynamics relationships. He has expertise in the development of liquid chromatographic-tandem mass spectrometric (LC-MS/MS) methods for the quantification of small molecules, including anti-infectives, in a variety of biological matrices. His laboratory focuses on studies aimed at understanding the pharmacology of long-acting antiretroviral drug delivery systems, the use of antiretrovirals as pre-exposure prophylactic agents, and the use of drugs as topical microbicides. Dr. Marzinke is also interested in the development and incorporation of targeted pharmacogenetics testing into the clinical environment.

Selected Publications

View all on PubMed

Marzinke MA, Choi CH, Chen L, Shih IM, Chan DW, Zhang H. Proteomic Analysis of Temporally Stimulated Ovarian Cancer Cells for Biomarker Discovery. Mol Cell Proteomics 2013; 12(2): 356-368.

Marzinke MA, Clarke W, Wang L, Cummings V, Liu TY, Piwowar-Manning E, Breaud A, Griffith S, Buchbinder S, Shoptaw S, Del Rio C, Magnus M, Mannheimer S, Fields SD, Mayer KH, Wheeler DP, Koblin BA, Eshleman SH, Fogel JM. Nondisclosure of HIV Status in a Clinical Trial Setting: Antiretroviral Drug Screening Can Help Distinguish Between Newly Diagnosed and Previously Diagnosed HIV Infection. Clin Infect Dis. 2014 Jan;58(1):117-20. PMID: 24092804.

Seserko LA, Emory JF, Hendrix CW, Marzinke MA. The development and validation of an UHPLC-MS/MS method for the rapid quantification of the antiretroviral agent dapivirine in human plasma. Bioanalysis. 2013; 5(22):2771-83. PMID: 24256358.

Petrides AK, Clarke W, Marzinke MA. Application and utility of pharmacogenetics in the clinical laboratory. J Analyt Molecul Tech. 2014; 1(1): 15.

Marzinke MA, Breaud A, Parsons TL, Cohen MS, Piwowar-Manning E, Eshleman SH, Clarke W. The development and validation of a method using high-resolution mass spectrometry (HRMS) for the qualitative detection of antiretroviral agents in human blood. Clin Chim Acta, 2014; 433C: 157-168.

Activities & Honors


  • Young Investigators’ Day Award, 2012
  • Diplomate, American Board of Clinical Chemistry, 2012
  • Fellow, National Academy of Clinical Biochemistry, 2014
  • George Grannis Award, National Academy of Clinical Biochemistry, 2015
  • Young Investigator Award, American Association for Clinical Chemistry, 2017
Is this you? Edit Profile
back to top button